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Abstract
Objective
A number of observational studies have shown an inverse association between circulating
25-hydroxyvitamin D and total mortality, but a reverse J-shaped association has also been
reported. In a large nested case-control study, serum-25-hydroxyvitamin D (s-25(OH)D)
was positively associated with incident prostate cancer. Based on the same study popula-
tion, the primary aim of the present study was to investigate the association between s-25
(OH)D and total mortality.
Methods
Men participating in population based health screenings during 1981–1991 and enrolled in
a nested case-control study were followed throughout 2007 with respect to all-cause and
cause-specific mortality. Hazard ratios (HR) with 95% confidence intervals (CI) were calcu-
lated using Cox proportional hazards regression.
Results
In men with prostate cancer (n = 2282), there was a significant inverse association between
s-25(OH)D and total mortality after controlling for potential confounders (HR = 1.25 (95% CI
1.05–1.50), s-25(OH)D <50 nmol/l versus s-25(OH)D50 nmol/l). The corresponding figure
among controls (n = 2147) was HR = 1.15 (95% CI 0.88–1.50) and in the total study
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Data Availability Statement: Due to legal restriction
the data set cannot be made publicly available. Part
of the dataset is provided by Statistics Norway, and
according to Norwegian law, we are not allowed to
make this individual level information available
outside Norway. According to ‘Statistikkloven’, the law
regulating statistical information handled by Statistics
Norway, it is not allowed to send individual level
information they provide out of the country, even if the
data is anonymous. In our dataset, this applies to
education. This means that if someone wishes to
analyze the complete dataset, it needs to be done on
population HR = 1.19 (95% CI 1.03–1.38). For cause-specific deaths, we found no signifi-
cant associations.
Conclusions
In this study population, s-25(OH)D was inversely associated with total mortality during
more than two decades of follow-up, despite, as previous reported, high s-25(OH)D was
associated with increased risk of prostate cancer.
Introduction
A number of observational studies have assessed the association between circulating 25-hydro-
xyvitamin D and mortality, indicating a potential beneficial role of vitamin D. Most studies
have reported increased mortality in individuals low in vitamin D, and according to a recent
analysis of eight cohort studies [1], low serum 25-hydroxyvitamin D (s-25(OH)D) was related
to increased all-cause and cardiovascular mortality. In addition, low s-25(OH)D was related to
cancer mortality in subjects with a history of cancer but not in subjects without a history of
cancer, suggesting that vitamin D influences the prognosis of cancer.
A Danish study recently showed that both low plasma 25-hydroxyvitamin D and genetic
variants, affecting the concentration of 25-hydroxyvitamin D, were associated with increased
total mortality [2]. The polymorphisms were also associated with cancer mortality, non-cancer
non-CVDmortality, but not with CVDmortality.
In addition, randomized controlled trials have reported an effect of vitamin D supplementa-
tion on mortality. Most of these studies were set up to study fractures, and some of them co-
supplemented with calcium. According to a recent Cochrane review, vitamin D3 supplementa-
tion slightly decreases all-cause mortality (RR 0.94 (95% CI 0.91 to 0.98)) [3]. However, the
result was not considered robust enough to recommend widespread supplementation, and
there are several large-scale trials underway to study if vitamin D supplementation can reduce
mortality [4].
Vitamin D might affect mortality through different mechanisms. The vitamin D receptor
and the enzyme 1-α-hydroxylase required for activation of vitamin D are present in many
organs and tissue [5]. The human genome has many binding sites for vitamin D, suggesting
regulation of many genes [6]. Vitamin D has also been positively associated with leucocyte telo-
mere length, a predictor of longevity and age-related diseases [7].
On the other hand, some cohort studies have reported a reverse J-shaped association also
indicating increased mortality associated with high concentration of vitamin D [5, 8–10].
There are several concerns when assessing the effect of vitamin D in observational studies.
High s-25(OH)D might be an indicator of a general healthy lifestyle. Diseases might directly or
indirectly cause low vitamin D-status with the possibility of reverse causation [11].
As previously reported, high s-25(OH)D was associated with an increased risk of prostate
cancer in a large Norwegian nested case-control study [12]. Interestingly, only subjects with
samples collected during summer and autumn showed this association, while no relation was
observed in subjects with serum collected during winter or spring.
In the present study, based on the same study population, the primary aim was to investi-
gate the association between s-25(OH)D and total mortality and secondarily between s-25
(OH)D and casus-specific mortality. Thus, we ask the question, did the increased risk of pros-
tate cancer associated with high concentration of s-25(OH)D translate into increased mortality,
or was the opposite the case?
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Material and Methods
As previously described[12], data from population based standardized cardiovascular health
screenings carried out in 17 of Norway’s 19 counties during 1981–1991 by the National Health
Screening Service (later Norwegian Institute of Public Health) were used, except for the capital
city of Oslo where the local health authority conducted the study. All men and women in
selected birth cohorts residing in the counties were invited to participate, and in men the
median participation rate was 71% (range: 55–88%). Measurement of blood pressure, height
and weight were included in the health examination, and body mass index (BMI) (kg/m2) was
calculated. A non-fasting blood sample was drawn for analyses of blood lipids, and residual
serum was stored at –25°C in the JANUS serum bank (http://www.kreftregisteret.no/en/
Research/Janus-SerumBank/). As described earlier, total s-25(OH)D, including s-25(OH)D3
and s-25(OH)D2, was determined at Vitas, Oslo, Norway, by HPLC atmospheric pressure
chemical ionization mass spectrometry (MS) [12].
The participants also filled in a questionnaire including history and symptoms of cardiovas-
cular disease and questions on physical activity and smoking history. Physical activity during
leisure time was assessed by a four graded question. Information on education was received
from the Norwegian National Education Database at Statistics Norway.
Data on 122,083 men participating in the health screenings were linked to the Cancer Regis-
try of Norway. It was required that all cancer cases had donated serum at least one year before
diagnosis. In all, 2282 men who were diagnosed with prostate cancer after screening and
throughout 2006 were included.
In the original data setup for the matched case-control study [12], one control was selected
for each case matched for age at serum sampling (±6 months), date of serum sampling (±2
months), and health examination. Controls were alive and free from cancer at the time of diag-
nosis of the corresponding case. As controls could randomly be selected several times accord-
ing to the protocol, we obtained 2147 unique controls. Fifty persons were excluded due to
missing data. Thus, the final dataset included 4379 men (2259 cases and 2120 controls).
The participants in the original case-control study have been followed with respect to total
and cause-specific mortality by linkage to the National Population Registry and the Cause of
Death Registry. Follow-up time was calculated from the index date, that is the date of prostate
cancer diagnosis for cases and the diagnosis date of the matched case for the controls, to the
date of death or throughout 2007.
Statistics
Descriptive characteristics of the study population are presented as means with standard devia-
tion (SD) and frequencies (%), according to s-25(OH)D.
Hazard ratios (HR) with 95% confidence intervals (CI) were calculated using Cox propor-
tional hazards regression models with follow-up from index date. The data was analysed not
taking the original matching into account. Instead, adjustment was made to account for the
matching (case/control status (applies only for the complete dataset), age, month of serum
sampling, and health examination). In addition, we adjusted for education (primary, second-
ary, and university or college), BMI, smoking (current cigarette smoking yes/no) and physical
activity during leisure time (sedentary, moderate, intermediate, and intensive). To produce
spline curves, s-25(OH)D was included as restricted cubic splines with five knots.
In an alternative analysis, we analysed the complete dataset (n = 4379) as a matched cohort
study utilizing stratified Cox proportional hazards regression models. The results were similar
(S1 Appendix), but the statistical power was lower. We therefore present the data from the un-
stratified Cox model.
Long Term Association between 25-Hydroxyvitamin D and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151441 March 17, 2016 3 / 11
In addition, we performed a competing risk analysis in the prostate cancer cases by the
stcrreg command in STATA in order to estimate the cumulative mortality in groups of s-25
(OH)D when considering the two competing events: deaths from prostate cancer (underlying
cause, n = 381) and death from all other causes (n = 228).
For comparison we also re-analyzed the association between s-25(OH)D and prostate cancer
by a weighted Cox-regression [13, 14] adjusted for age, month of blood sampling, examination
and education to obtain comparable hazard ratios. The weights were estimated with logistic
regression and the approach enables us to break the matching between cases and controls.
Data were analysed by IBM SPSS 22, STATA 13.1 and R (R Core Team. R: A Language and
Environment for Statistical Computing. http://www.R-project.org/).
The study was approved by the Regional Committee for Medical Research Ethics of Western
Norway.
Results
During follow-up, 609 of 2259 men with prostate cancer (27%) and 267 of 2120 men without
prostate cancer (12.6%) died. Mean time from blood sample collection to the end of follow-up
was 21.1 (SD±4.0) years. Mean time from blood sample collection to death was 16.8 (SD±5.6)
years and only 2.3% of the deaths occurred within 5 years and 12% of the deaths occurred
within 10 years from blood collection. Mean follow-up time from the time of diagnosis (index
date) was 4.7 (SD±3.4) years.
Baseline concentration of s-25(OH)D was inversely associated with BMI and being a current
cigarette smoker, positively associated with physical activity and education whereas there was
no clear association with height and total serum cholesterol (Table 1)
As can be seen in Table 2, there was an inverse association between baseline s-25(OH)D
concentration and total mortality both in men with and without prostate cancer. Further
Table 1. Characteristics of the study population at baseline by s-25(OH)D concentration.
s-25(OH)D (nmol/l)
< 30 30–49 50–69 70–89 90
N 160 1141 1561 1023 494
s-25(OH)D (nmol/l)a 25.5 (3.9) 41.7 (5.4) 59.7 (5.7) 78.5 (5.6) 105.6 (16.5)
Agea 47.1 (8.8) 47.6 (8.6) 48.5 (9.4) 48.6 (9.4) 48.0 (9.1)
BMI (kg/m2) a 26.0 (3.7) 25.9 (3.1) 25.7 (2.9) 25.3 (2.9) 24.7 (2.6)
Height (m) a 1.77 (.07) 1.77 (.07) 1.77 (.07) 1.77 (.06) 1.77 (.07)
Leisure time activity (%)
Sedentary 28% 21% 15% 14% 11%
Moderate 56% 55% 55% 53% 52%
Intermediate 15% 23% 28% 30% 33%
Intensive 1% 1% 2% 3% 4%
Current cigarette smoker (%) 49% 41% 31% 29% 28%
Total serum cholesterol (mmol/l) a 6.0 (1.1) 6.1 (1.2) 6.1 (1.1) 6.1 (1.1) 6.0 (1.1)
Education (%)
Primary 40% 38% 32% 36% 30%
Secondary 46% 47% 48% 43% 48%
University or college 14% 15% 20% 21% 22%
a Mean±SD
doi:10.1371/journal.pone.0151441.t001
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adjustment for BMI, smoking, physical activity and education attenuated the associations mod-
erately, and the association remained significant in men with prostate cancer only. According
to spline analyses (Fig 1), the curves showing the association between s-25(OH)D and total
mortality were relatively flat at concentration higher than 60–70 nmol/l, and there was no indi-
cation of increased risk in those with the highest concentration of s-25(OH)D. In the analyses
restricted to men with prostate cancer, the HR for total mortality in men with s-25(OH)D< 50
nmol/l was HR = 1.25 (95% CI 1.05–1.50) in the fully adjusted model, compared to men with
higher s-25(OH)D. The corresponding HR in the controls was 1.15 (95% CI 0.88–1.50) and in
the total study population the HR was 1.19 (95% CI 1.03–1.38).
In those with prostate cancer, we also analyzed the data according to underlying causes of
death, grouping them into deaths from cancer (cancer deaths, n = 460), cardiovascular diseases
(CVD deaths, n = 96), and all other causes (non-CVD, non-cancer deaths, n = 53). No signifi-
cant associations were found although the estimates suggested a moderate increased mortality
in those with low vitamin D status (Table 3). For deaths from prostate cancer (underlying
cause, n = 381), the HR per 20 nmol/l decrease in s-25(OH)D was 1.06 (95% CI 0.96–1.17),
and the HR for those having s-25(OH)D concentration< 50 nmol/l compared to 50 nmol/l
was 1.15 (0.91–1.45).
In analyses restricted to blood samples collected during winter/spring in those with prostate
cancer, the HR for prostate cancer deaths was 1.15 (95% CI 0.97–1.35) per 20 nmol/l decrease
in s-25(OH)D. The corresponding result for men with blood samples collected during sum-
mer/autumn was 1.03 (95% CI 0.90–1.17).
Results from the competing risk analyses, restricted to men with prostate cancer, are shown
in Fig 2. The cumulative incidence of deaths from other causes was higher in those with s-25
(OH)D< 50nmol/l compared to those with s-25(OH)D 50 nmol/l (p = 0.015), whereas the
Table 2. Hazard ratio (HR) and 95% confidence intervals (95%CI) for total mortality by concentration
of s-25(OH)D.
25(OH)D (nmol/l) n Deaths, n (%) HR (95% CI)a HR (95% CI)b
Men with prostate cancer
< 30 74 24 (32.4) 1.60 (1.04, 2.46) 1.43 (0.93, 2.22)
30–49 571 172 (30.1) 1.32 (1.07, 1.63) 1.28 (1.03, 1.58)
50–69 781 200 (25.6) 1.00 (ref) 1.00 (ref)
70–89 563 148 (26.3) 1.10 (0.89, 1.37) 1.10 (0.89, 1.37)
 90 270 65 (24.1) 0.95 (0.71, 1.26) 0.97 (0.73, 1.30)
P linear trend 0.028 0.095
HR per 20 nmol/l decreasec 1.09 (1.01, 1.18) 1.07 (0.99, 1.16)
Men without prostate cancer
< 30 86 8 (9.3) 0.92 (0.44, 1.93) 0.90 (0.42, 1.90)
30–49 570 81 (14.2) 1.23 (0.91, 1.66) 1.13 (0.83, 1.52)
50–69 780 99 (12.7) 1.00 (ref) 1.00 (ref)
70–89 460 59 (12.8) 0.93 (0.67, 1.29) 0.95 (0.68, 1.32)
 90 224 20 (8.9) 0.82 (0.51, 1.34) 0.82 (0.50, 1.34)
P linear trend 0.025 0.083
HR per 20 nmol/l decreasec 1.16 (1.02, 1.32) 1.12 (0.99, 1.28)
a HR estimated by Cox regression adjusted for age, month of blood sampling and examination
b Additionally adjusted for physical activity, BMI, smoking and education
c Per 20 nmol/l decrease in s-25(OH)D entered as a continuous variable
doi:10.1371/journal.pone.0151441.t002
Long Term Association between 25-Hydroxyvitamin D and Mortality
PLOS ONE | DOI:10.1371/journal.pone.0151441 March 17, 2016 5 / 11
corresponding difference was not significant in the analysis with cumulative incidence of death
from prostate cancer (p = 0.41).
In analyses restricted to men without prostate cancer, the HR per 20 nmol/l decrease in s-25
(OH)D was 0.94 (95% CI 0.75–1.18) for cancer deaths (n = 69), 1.20 (95% CI 0.98–1.47) for
CVD deaths (n = 117), and 1.23 (95% CI 0.97–1.57) for non-CVD non-cancer deaths (n = 81).
Analysing the prostate cancer cases and controls groups together, there was no interaction
between having prostate cancer or not and s-25(OH)D (pinteraction = 0.39) on mortality. As the
HR’s for death in the different categories of s-25(OH)D was rather similar in men with and
Fig 1. Hazard ratios (solid lines) with 95% confidence intervals (dashed lines) for all-cause mortality across
the distribution of 25(OH)D in (A) men with prostate cancer and in (B) men without prostate cancer. Adjusted
for age, month of blood sampling, examination, physical activity, BMI, smoking and education. 25(OH)D was
included as restricted cubic splines with five knots.
doi:10.1371/journal.pone.0151441.g001
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without prostate cancer (except for those with s-25(OH)D< 30 nmol/l), a combined analysis
is shown in Fig 3: The overall result in this study population was an inverse association between
s-25(OH)D and all-cause mortality. In addition we reproduced the previously reported finding
Table 3. Hazard ratio (HR) and 95% confidence interval (95% CI) for cause specifics deaths in patients
with prostate cancer.
s-25(OH)D, (nmol/l) n Deaths, n (%) HR (95% CI)a
Cancer deaths
< 50 645 146 (22.6) 1.20 (0.97, 1.48)
 50 1614 314 (19.5) 1.00 (reference)
HR per 20 nmol/l decreaseb 1.06 (0.97, 1.16)
CVD deaths
< 50 645 30 (4.7) 1.40 (0.88, 2.23)
 50 1614 66 (4.1) 1.00 (reference)
HR per 20 nmol/l decreaseb 1.06 (0.87, 1.28)
Non-CVD non-cancer deaths
< 50 645 20 (3.1) 1.52 (0.83, 2.78)
 50 1614 33 (2.0) 1.00 (reference)
HR per 20 nmol/l decreaseb 1.18 (0.89, 1.56)
a HR estimated by Cox regression adjusted for age, month of blood sampling, examination, physical
activity, BMI, smoking and education
b Per 20 nmol/l decrease in s-25(OH)D entered as a continuous variable
doi:10.1371/journal.pone.0151441.t003
Fig 2. Cumulative mortality from other causes than prostate cancer (A) and cumulative mortality from prostate cancer (B), in men with a prostate cancer
diagnosis (n = 2259) according to strata of 25(OH)D concentration. Adjusted for age, month of blood sampling, examination, physical activity, BMI, smoking
and education. Death from prostate cancer (n = 381) and death from all other causes (n = 228) was set as competing events in panel A and B, respectively.
doi:10.1371/journal.pone.0151441.g002
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[12] of an increasing risk of incidence of prostate cancer by increasing concentration of s-25
(OH)D.
Discussion
In this study population, low s-25(OH)D was associated with increased risk of total mortality
during more than two decades of follow-up from the blood sample collection, whereas as previ-
ous reported, high s-25(OH)D was associated with increased risk of incident prostate cancer
[12].
The inverse association between s-25(OH)D and total mortality is in agreement with
numerous other studies [1, 2, 15–17]. The association was, however, not strong with a roughly
10% decreased mortality by a 20 nmol/l increase in s-25(OH)D, comparable in magnitude to
what was found in a large British cohort study [16] and meta-analyses of prospective cohort
studies [15, 17]. On the other hand, if there is a causal effect of vitamin D on mortality, there is
reason to believe that this effect is not very large. According to the Cochrane review on this
topic, supplementation with vitamin D3 modestly decreases all-cause mortality with 6%
(RR = 0.94 (95% CI 0.91 to 0.98)) [3]. On the other hand, some observational studies have
reported increased mortality in those with the highest concentration of 25(OH)D [8–10]. We
did not find any indication of this in spite of increased incidence of prostate cancer by increas-
ing s-25(OH)D. However, few men in our study had very high concentration of s-25(OH)D
(1.1% had concentration 125 nmol/l and 6% had concentration 100 nmol/l). In those with
blood collected during summer (June through August), 12.9% had concentrations> = 100
Fig 3. Hazard Ratios (HR) with 95% confidence intervals for total mortality (red line) and incident prostate cancer (blue line) by category of s-25
(OH)D. Separate analyses were performed for the two endpoints. 25(OH)D 50–69 nmol/l is the reference category. In the total mortality analysis, adjustment
was made for age, case status, month of blood sampling, examination, physical activity, BMI, smoking and education. In the prostate cancer incidence
analysis adjustment was made for age, month of blood sampling, examination and education.
doi:10.1371/journal.pone.0151441.g003
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nmol/l, indicating that sun exposure was an important determinant for high s-25(OH)D in the
study population.
Some other studies have also reported increased risk of incident prostate cancer at high con-
centrations of circulating 25-hydroxyvitamin D [18–21]. Although our study had limited statis-
tical power to study cause specific mortality, it is reassuring that the increased risk of incident
prostate cancer was not translated into increased risk of fatal prostate cancer as a non-signifi-
cant inverse association between increasing s-25(OH)D and fatal prostate cancer was found.
Also in an alternative analyses of the total study population, there was no significant associa-
tion between s-25(OH)D and death from prostate cancer [13]. In a previous Norwegian study
of 160 patients with prostate cancer, s-25(OH)D in blood samples collected close to the time of
diagnosis (±3 months) was inversely associated with death from prostate cancer [22]. One
American study also found that plasma 25-hydroxyvitamin D was inversely and statistically
significantly related to fatal prostate cancer [23], whereas this was not confirmed in an
extended analysis in the Breast and Prostate Cancer Cohort Consortium (518 fatal cases) with
an odds ratio of 0.86 (95% CI 0.65–1,14) in the highest compared to the lowest quartile of cir-
culating 25-hydroxyvitamin D [24]. This is in line with our results (381 fatal cases) with a RR
of 0.93 (95% CI 0.69–1.23) in the highest compared to the lowest quartile of s-25(OH)D.
In general, the effect of vitamin D might be stronger for mortality of cancer than for inci-
dence of cancer. In a recent meta-analysis of randomized controlled trials, no effect of vitamin
D supplementation was found on cancer incidence (400–1100 IU per day over 2–7 years),
whereas a 12 percent reduction in total cancer mortality was reported [25].
The mechanisms for an effect of vitamin D on total mortality are not clear but could act via
different pathways. Many genes are regulated by vitamin D [6], and many organ and tissues
have vitamin D receptors and the enzyme 1-α-hydroxylase required for activation of vitamin D
[5]. In addition to vitamin D’s effects on calcium and bone metabolism, vitamin D might have
many extra-skeletal effects, including an influence on cell proliferation and differentiation, the
immune system, the cardiovascular system, metabolism and the neurological system. It is thus
biologically plausible that vitamin D might positively influence on a number of diseases, and
this seems to be supported by observational studies [5]. In a recent meta-analysis of primary
prevention cohorts, high circulating 25-hydroxyvitamin D was inversely associated both with
cardiovascular deaths, cancer deaths and deaths due to other causes [15]. This is somewhat in
line with the cause-specific analyses in our study, although these results were not statistically
significant and had wide confidence intervals.
A limitation of our study was that only one measurement of s-25(OH)D from each partici-
pant was available, but as discussed in the previous publication, the correlation coefficient
between two measurements up to 14 years apart have been reported to be about 0.5 [12].
Another limitation was the limited statistical power to study cause-specific mortality. In the
prostate cancer cases, no Gleason grading was available. As discussed in the first paper [12],
increased detection of prostate cancer in those with high s-25(OH)D is probably not the case in
this study population as adjustment for education had very little impact on the estimates and
there was no association between s-25(OH)D and localized cancer. Although we adjusted for
important confounders, residual confounding cannot be excluded. Strength of this study was a
very long follow-up with few of the deaths occurring the first years after blood sample collec-
tion, reducing the risk of reverse causation. The statistical power to study total mortality was
good. The participants were recruited from the general Norwegian population, but were
restricted to men with prostate cancer and their matched controls without cancer at the time of
diagnosis of their counterpart.
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In conclusion, in this prospective study, low concentration of s-25(OH)D was associated
with increased mortality during more than two decades of follow-up, and as previously
reported, it was associated with decreased incidence of prostate cancer.
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